{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:59:11Z","timestamp":1787313551762,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.lungcan.2020.11.022","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T02:11:54Z","timestamp":1606356714000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma"],"prefix":"10.1016","volume":"152","author":[{"given":"Paolo","family":"Ghirardelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"D\u2019Aveni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Dominici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ravasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Marzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Di Noia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Scorsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Vavassori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni L.","family":"Ceresoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2020.11.022_bib0005","first-page":"402","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2020.11.022_bib0010","first-page":"1343","article-title":"A proposed system toward standardizing surgical-based treatments for malignant pleural mesothelioma, from the Joint National Cancer institute \u2013 International Association for the Study of Lung Cancer \u2013 Mesothelioma Applied Research Foundation Taskforce","volume":"14","author":"Friedberg","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.11.022_bib0015","first-page":"2636","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.11.022_bib0020","first-page":"1443","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.11.022_bib0025","first-page":"1213","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol."},{"issue":"Suppl","key":"10.1016\/j.lungcan.2020.11.022_bib0030","article-title":"Phase 2 multicenter study of antiPD-L1 durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)","volume":"38","author":"Forde","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.11.022_bib0035","article-title":"First-line nivolumab plus ipilimumab vs chemotherapy in unresectable malignant pleural mesothelioma: CheckMate 743","author":"Baas","year":"2020","journal-title":"Presented at 2020 Presidential IASLC Symposium, August 8th"},{"key":"10.1016\/j.lungcan.2020.11.022_bib0040","first-page":"1343","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 5","key":"10.1016\/j.lungcan.2020.11.022_bib0045","first-page":"v31","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2020.11.022_bib0050","first-page":"1655","article-title":"Current and future management of malignant mesothelioma: a consensus report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation","volume":"13","author":"Tsao","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.11.022_bib0055","first-page":"271","article-title":"Vinorelbine and gemcitabine as second or third-line therapy for malignant pleural mesothelioma","volume":"84","author":"Zauderer","year":"2014","journal-title":"Lung Cancer."},{"key":"10.1016\/j.lungcan.2020.11.022_bib0060","first-page":"73","article-title":"Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma","volume":"72","author":"Ceresoli","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2020.11.022_bib0065","first-page":"239","article-title":"Nivolumab or nivolumab plus ipilimumab in patients withrelapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"issue":"September","key":"10.1016\/j.lungcan.2020.11.022_bib0070","article-title":"A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"22","author":"Popat","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2020.11.022_bib0075","first-page":"e161","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol."},{"issue":"Suppl","key":"10.1016\/j.lungcan.2020.11.022_bib0080","article-title":"Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): results of Italian Rames Study","volume":"38","author":"Pagano","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.11.022_bib0085","first-page":"37","article-title":"Pain management in patients with malignant mesothelioma: challenges and solutions","volume":"10","author":"Saunders","year":"2019","journal-title":"Lung Cancer (Auckl)"},{"key":"10.1016\/j.lungcan.2020.11.022_bib0090","first-page":"e532","article-title":"Radiotherapy for the treatment of malignant pleural mesothelioma","volume":"18","author":"de Perrot","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2020.11.022_bib0095","first-page":"1","article-title":"The role of radical radiotherapy in the management of malignant pleural mesothelioma: a systematic review","volume":"125","author":"Ashton","year":"2017","journal-title":"Radiother. Oncol."},{"issue":"January 1","key":"10.1016\/j.lungcan.2020.11.022_bib0100","article-title":"Radical multimodality therapy for malignant pleural mesothelioma","volume":"8","author":"Abdel-Rahman","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.lungcan.2020.11.022_bib0105","first-page":"1651","article-title":"Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17\/04): a randomized, international, multicenter phase II trial","volume":"16","author":"Stahel","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2020.11.022_bib0110","first-page":"1172","volume":"14","author":"Gomez","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.11.022_bib0115","first-page":"1393","article-title":"Cyberknife radiosurgery for focal paravertebral recurrence after radical pleurectomy\/decortication in malignant pleural mesothelioma","volume":"41","author":"Lang-Lazdunski","year":"2012","journal-title":"Eur. J. Cardiothor. Surg."},{"key":"10.1016\/j.lungcan.2020.11.022_bib0120","first-page":"961","article-title":"Stereotactic body radiation therapy (SBRT) as salvage therapy for oligorecurrent pleural mesothelioma after multimodality therapy","volume":"9","author":"Schr\u00f6der","year":"2019","journal-title":"Front. Oncol."},{"issue":"February (2)","key":"10.1016\/j.lungcan.2020.11.022_bib0125","first-page":"257","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2020.11.022_bib0130","first-page":"475","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lungcan.2020.11.022_bib0135","first-page":"343","article-title":"Emerging treatments for malignant pleural mesothelioma. Where are we heading?","volume":"10","author":"Cantini","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2020.11.022_bib0140","first-page":"697","article-title":"Immune checkpoint inhibition for the treatment of mesothelioma","volume":"19","author":"Nowak","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.lungcan.2020.11.022_bib0145","first-page":"72","article-title":"A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma","volume":"141","author":"Petrelli","year":"2018","journal-title":"Respir. Med."},{"key":"10.1016\/j.lungcan.2020.11.022_bib0150","first-page":"527","article-title":"Radiation sensitivity of human lung cancer cell lines","volume":"25","author":"Carmichael","year":"1989","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.11.022_bib0155","first-page":"511","article-title":"Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura--a single-institution experience with 189 patients","volume":"43","author":"De Graaf-Strukowska","year":"1999","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2020.11.022_bib0160","first-page":"12468","article-title":"Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model","volume":"6","author":"Wu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2020.11.022_bib0165","first-page":"867","article-title":"Mesothelioma cells depend on the anti-apoptotic protein Bcl-xL for survival and are sensitized to ionizing radiation by BH3-mimetics","volume":"106","author":"Jackson","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022030698X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022030698X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:44:11Z","timestamp":1759236251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022030698X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":33,"alternative-id":["S016950022030698X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.11.022","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}